Compare NMZ & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMZ | SPTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2026 |
| Metric | NMZ | SPTX |
|---|---|---|
| Price | $9.32 | $22.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 885.0K | 121.4K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $17.59 |
| 52 Week High | $10.77 | $28.38 |
| Indicator | NMZ | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 17.29 | 47.86 |
| Support Level | N/A | $18.72 |
| Resistance Level | $10.54 | $28.38 |
| Average True Range (ATR) | 0.10 | 2.24 |
| MACD | -0.06 | -0.26 |
| Stochastic Oscillator | 2.33 | 20.28 |
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.